Julio G. Martinez-Clark CEO of Bioaccess and President of IAOCR/GCSA Americas is a MedTech trailblazer helping startups accelerate First-in-Human (FIH) clinical trials across Latin America, with over 20 years of experience spanning healthcare, telecom and venture capital

In this episode, we unpack why more MedTech companies are turning to LATAM for faster, more cost-effective trial execution. Julio shares how his Miami-based CRO helps deliver 58-day CE mark approvals, his experience supporting 100+ device startups and why time, not money, is the most precious currency for early-stage founders. We also touch on trial quality, regulatory strategy and why he believes Latin America will play a defining role in the next era of global MedTech innovation

Timestamps:

[00:00:47] Why LATAM Is the Next MedTech Trial Hub

[00:02:21] The Problem with FIH Trials in the U.S.

[00:04:42] How bioaccess® Reduces Approval Timelines by 70%

[00:06:01] Strategic Sites, Patient Retention & CRO Infrastructure

[00:08:17] Do LATAM Trials Hold Up to FDA & EU Scrutiny?

[00:10:43] The Fundraising Pressure Behind Faster Clinical Results

[00:12:22] Founder Mistakes in In-House Trial Management

[00:14:11] Why LATAM May Overtake Eastern Europe in FIH Volume

[00:17:26] Regulatory Standards, UNESCO, and Regional Quality

[00:20:10] Julio Outside the Office: Family, Fitness & Podcasting

Get in touch with Julio - https://www.linkedin.com/in/juliomartinezclark/

Learn more about Bioaccess - https://www.bioaccessla.com/

Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/

Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwal

Subscribe to the Podcast